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Purpose: The results of all prostate biopsies may be positive and suggestive of ad-
enocarcinoma in patients with prostate-specific antigen (PSA) values higher than 100 
ng/ml. We considered that the prostate cancer in patients with high PSA might be ad-
vanced disease and therefore that the treatment strategy should not be changed accord-
ing to pathological reports. Thus, we assessed the role of prostate biopsy when diagnos-
ing prostate cancer in patients with extremely high PSA levels.
Materials and Methods: We reviewed the records of 1,150 cases undergoing prostate 
biopsies. Patients with urinary tract infection and acute urinary retention were 
excluded. According to the pre-biopsy PSA level, patients were divided into 6 groups 
(group A, 4 to 20 ng/ml; B, 20 to 40 ng/ml; C, 40 to 60 ng/ml; D, 60 to 80 ng/ml; E: 80 
to 100 ng/ml; and F, above 100 ng/ml). 
Results: The calculated positive predictive value (PPV) for prostate cancer was 22% 
in group A, 54% in group B, 73% in group C, 75% in group D, 89% in group E, and 100% 
in group F, respectively. Pathological diagnosis was adenocarcinoma in all patients in 
group F (n=56). Among them, 38 patients (67.9%) had lymph node metastasis or ex-
tra-prostatic disease or both and 43 patients (76.8%) had bony metastasis. In group 
F, all cases were advanced prostate cancer (stage III or IV). All of them received hormo-
nal therapy following diagnosis. 
Conclusions: We suggest the possibility for biopsy-free diagnosis of prostate cancer in 
patients with extremely high levels of serum PSA and evidence of advanced disease 
in imaging studies, especially in older patients with comorbid medical problems. 
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INTRODUCTION
The incidence of prostate cancer has been gradually in-
creasing in Korea. The increase in the aged population, a 
westernized lifestyle, the development of diagnostic tools, 
and national surveillance programs for early prostate can-
cer detection may all have contributed to the increased de-
tection rate of prostate cancer. 
Checking the serum prostate-specific antigen (PSA) lev-
el and a digital rectal examination (DRE) are the gold 
standards for prostate cancer screening. If repeated PSA 
levels exceed 4 ng/ml or prostate nodule or asymmetry are 
found by DRE, transrectal ultrasonography (TRUS)-gui-
ded needle biopsy is performed to pathologically confirm 
the diagnosis [1,2].
A higher PSA value is more frequently associated either 
with prostate cancer or with advanced disease, even 
though the opposite opinions have been reported in some 
cases (e.g., prostate cancer prediction with low PSA in the 
case of elderly patients with abnormal DRE and TRUS 
findings) [3]. More than 50% of men with a PSA value high-
er than 10 ng/ml have extra-prostatic disease. Twenty per-
cent of men with a PSA higher than 20 ng/ml and 75% of 
those with a PSA higher than 50 ng/ml are found to have Korean J Urol 2012;53:82-86
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FIG. 1. Positive predictive values according to prostate-specific 
antigen (PSA) range.
FIG. 2. The percentage of high-grade cancers (Gleason score ≥8). 
PSA, prostate-specific antigen.
pelvic lymph node involvement [4].
Common complications of prostate biopsy include post- 
biopsy infections and bleeding. Coagulopathy and immu-
nosuppression can be problematic, and severe conditions 
are contraindications to prostate biopsy. After TRUS-guid-
ed needle biopsy, most infectious complications are limited 
to symptomatic urinary tract infection and low-grade fe-
brile illness; however, recent studies showed that 1.4% of 
patients will go on to develop a febrile urinary tract in-
fection, bacteremia, or acute prostatitis and require hospi-
talization for treatment with intravenous antibiotics [5].
Bleeding is the most common complication seen after 
prostate biopsy, even with normal coagulation parame-
ters. It can present as hematuria, rectal bleeding, or hema-
tospermia. Other complications include acute urinary re-
tention (AUR), which may require temporary catheter-
ization, the chance of which is increased with a prior history 
of benign prostatic hyperplasia and older age [6,7].
Therefore, particularly in patients with extremely ele-
vated serum PSA levels and old age, prostate biopsy to con-
firm the diagnosis of prostate cancer should be carefully 
considered owing to possibly fatal complications. To prove 
the necessity for prostate biopsy in this group, we reviewed 
the outcomes of TRUS-guided prostate needle biopsy in pa-
tients with elevated PSA levels. We grouped the patients 
according to their PSA levels and calculated the positive 
predictive value (PPV).
MATERIALS AND METHODS
We retrospectively reviewed the medical records of 1,150 
patients who underwent TRUS-guided prostate needle bi-
opsy for the evaluation of prostate cancer from January 
2000 to December 2010. Patients with a pre-biopsy PSA 
level less than 4 ng/ml were excluded from the study. We 
also excluded patients with acute prostatitis and acute uri-
nary retention. In total, 1,121 patients were reviewed in 
this study. 
All patients took antibiotic prophylaxis (either PO qui-
nolones or third-generation cephalosporins) for 7 days, 
starting from the day before the biopsy. If any signs or 
symptoms suggesting urinary tract infection occurred, the 
procedure was canceled. Patients taking anticoagulation 
agents stopped the medication for at least 5 days before the 
biopsy. For most of the patients, 12-core or double sextant 
biopsy (i.e., right peripheral 3 core, right medial 3 core, left 
peripheral 3 core, and left medial 3 core) was performed. 
One or more cores were added if suspicious hypoechoic le-
sions or palpable nodules were present on ultrasound or 
DRE. Some patients in poor general condition underwent 
standard sextant biopsy or 8-core biopsy.
According to the pre-biopsy PSA level, patients were div-
ided into 6 groups (group A, 4 to 20 ng/ml; B, 20 to 40 ng/ml; 
C, 40 to 60 ng/ml; D, 60 to 80 ng/ml; E, 80 to 100 ng/ml; and 
F, above 100 ng/ml). The patients’ age, pre-biopsy PSA lev-
el, the result of biopsy (i.e., cancer cell type and the Gleason 
score), and clinical or pathologic TNM stage were compa-
red. The cancer detection rate was analyzed for each group. 
RESULTS
Overall, 356 (31.8%) of the 1,121 patients had prostate 
carcinoma. The mean age of the patients with reported 
prostate cancer at biopsy was 65.8 years (range, 34 to 88 
years) and that of the patients with a negative biopsy result 
was 70.1 years (range, 38 to 91 years). The mean PSA level 
of the patients with a positive biopsy result was 16.12 ng/ml 
(range, 4.82 to 7,176 ng/ml). The mean PSA level of patients 
with a negative result was 10.39 ng/ml (range, 4.12 to 85.5 
ng/ml). The detection rate was gradually increased as the 
pre-biopsy PSA level increased. For example, only 21.8% 
of group A (i.e., PSA 4 to 20 ng/ml) had prostate cancer, 
whereas all 65 patients of group F (PSA ＞100 ng/ml) had 
cancer (positive predictive value=100.0%), as presented in 
Fig. 1. 
All 356 patients had prostate adenocarcinoma. Among 
them, 107 had high-grade cancer (Gleason score ≥8). The 
percentage of high-grade cancer was 30% in total, which in-
creased to 71% in group F (Fig. 2).
Magnetic resonance imaging (MRI) was used to evaluate 
the local extent of disease and the possibility of lymph node 
involvement, and radionuclide bone scans were also per-Korean J Urol 2012;53:82-86
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TABLE 1. TNM stages of prostate cancer
　Stage I or II III IV Total
Group A (PSA 4 to 20 ng/ml)
Group B (PSA 20 to 40 ng/ml)
Group C (PSA 40 to 60 ng/ml)
Group D (PSA 60 to 80 ng/ml)
Group E (PSA 80 to 100 ng/ml)
Group F (PSA ＞100 ng/ml)
Total
110 (63)
  36 (71)
    4 (27)
    3 (30)
    3 (60)
  0 (0)
156 (50)
  18 (11)
  0 (0)
    2 (13)
    1 (10)
  0 (0)
  4 (7)
25 (8)
  46 (26)
  15 (29)
    9 (60)
    6 (60)
    2 (40)
  52 (93)
130 (42)
174
  51
  15
  10
    5
  56
311
Values are presented as number of patients (%).
PSA, prostate-specific antigen.
formed to detect skeletal metastasis. If prostatectomy was 
performed, the radiologic findings and pathologic results 
were used to determine the TNM stage. Staging was possi-
ble for 311 of the 356 patients, whereas 45 patients had no 
record due to follow-up loss. A total of 156 patients (50%) 
had organ-confined cancer (Table 1). Of the 56 patients who 
underwent workup for TNM stage in group F (PSA ＞100 
ng/ml), 38 patients had either extra-prostatic diseases 
(cT3-4) or lymph node metastasis (N1), and 43 patients had 
positive bone scan metastasis (M1). Combining the results 
in group F, all patients had advanced prostate cancer (i.e., 
4 patients [7%] had stage III and the remaining 52 patients 
[93%] had stage IV cancer). No patient who underwent 
workup for TNM staging in group F had organ-confined 
cancer.
DISCUSSION
An elevated serum PSA level is one of the most important 
features suggestive of prostate cancer [8,9]. In most cases, 
the PSA cutoff of 4 ng/ml is a threshold for performing pros-
tate biopsy. However, the test is painful and invasive, and 
various complications have been reported in the literature, 
albeit not common. Most of the complications were minor 
and did not require hospitalization, but serious life-threat-
ening complications, such as sepsis, also occurred [10-13].
In general, the risk of prostate cancer is directly related 
to the PSA level. Our analysis demonstrated that a serum 
PSA level higher than 100 ng/ml was 100.0% accurate in 
predicting the presence of prostate cancer on tissue biopsy. 
Heyns et al. [14] reported similar results in a large unscree-
ned population. Using a subset of 716 patients with a PSA 
value higher than 4 ng/ml, they found a positive predictive 
value of 98% for PSA over 60 ng/ml. Gerstenbluth et al. [4] 
reported that, when increased to over 50 ng/ml, the serum 
PSA level was 98.5% accurate in predicting cancer. Thus, 
they suggested that some highly selected patients may not 
need to undergo prostate biopsy before androgen depriva-
tion therapy. There may be a disparity between these re-
ports and ours, possibly resulting from racial differences. 
In our results, the PPV for PSA over 50 ng/ml was merely 
81.2%, which was lower than the value in the other Western 
studies. In other words, the negative predictive value for 
PSA over 50 ng/ml was higher. It is well known that in-
cidence and disease characteristics vary with race [1,15]. 
Also, the number of patients who had PSA over 50 ng/ml 
was comparatively smaller, resulting in a difference in 
PPV from other Western studies.
In the study by Egawa et al. [1], prostate cancer was pres-
ent in 59.5% of patients with a PSA of 10 ng/ml or higher. 
Shim et al. [16] also reported that the risk of positive biopsy 
for PSA levels more than 100 ng/ml was 100%, which was 
quite similar to our results. Studies of Korean populations 
have also documented a positive predictive value of 93.8% 
with a PSA higher than 100 ng/ml and of 94.7% with a PSA 
higher than 50 ng/ml, which increased to 100.0% in con-
junction with an abnormal DRE [17]. In the present study, 
the detection rate was 100.0% in the subgroup of patients 
with a PSA of 100 ng/ml or higher.
In group E (PSA, 80 to 100 ng/ml), one patient with a neg-
ative biopsy result was followed up for 6 months and a sec-
ond prostate biopsy was performed, which confirmed pros-
tate cancer. We did not include this patient in group F but 
rather in group E. This is because this study was conducted 
to verify the necessity for prostate biopsy in diagnosing 
prostate cancer; thus, we considered the result of the initial 
biopsy, not the repeated. Thus, patients with carcinoma re-
ported at their repeated biopsy and not at their initial biop-
sy were classified as having a negative prostate cancer 
result. Gerstenbluth et al. [4] have suggested that a neg-
ative biopsy in patients with a PSA value of higher than 20 
ng/ml is often a false-negative. The likelihood of cancer is 
significantly increased if the PSA level is persistently high 
at a subsequent measurement. 
The most important role of prostate biopsy is to confirm 
the diagnosis pathologically, but it also helps to obtain the 
histologic subtype and to estimate the extent of disease 
(e.g., the number of positive cores and percentage of pos-
itive cores). Therefore, if cancer is expected to be present 
in almost 100% of a specific patient group, then the value 
of biopsy is reduced merely to histologic grading and esti-
mation of disease extent [18].
In our review, all 65 patients in group F (PSA ＞100 
ng/ml) had adenocarcinoma. Ninety percent of the patients 
had a Gleason grade of 4 or higher (i.e., Gleason score of 7 
or higher), and radiologic studies showed that all the can-Korean J Urol 2012;53:82-86
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TABLE 2. Characteristics of patients with a PSA level over 100 
ng/ml
Stage I-II III IV
Age (yr)
≤65
＞65
BMI (kg/m
2)
＜25
≥25
Gleason score
＜6
6 or 7
≥8
Positive core percentage (no. of 
positive cores/no. of biopsy cores) (%)
＜50
＜75
＜100
100
0
0
0
0
0
0
0
0
0
0
0
1
3
2
2
0
0
4
0
0
2
2
  7
45
33
19
  5
14
33
  5
  5
  6
36
Values are presented as number of patients (%).
BMI, body mass index.
cers were stage III or IV (Table 1). In addition, the charac-
teristics of the patients in group F are presented in Table 
2. The patient’s age, body mass index, Gleason score, and 
percentage of positive cores was investigated, but the re-
sults showed all patients to have high stages. Therefore, 
the information from the prostate biopsy (e.g., Gleason 
score and the number of positive cores) does not affect the 
treatment strategy. If advanced disease is suspected by a 
super-high PSA level and the results of imaging studies, 
definitive surgical treatment will not be an option. In our 
study, all 56 patients received androgen deprivation 
therapy. Thus, if cancer is suspected in 100% of the patient 
group, and both disease extent and histologic subtype can 
be expected to be in a narrow range, undergoing a needle 
biopsy would be of little value for this specific group (i.e., 
patients with extremely high levels of serum PSA).
Many other prostate diseases affect the PSA level. 
Inflammation due to infection has been found to produce 
significant PSA elevation, and up to 6 to 8 weeks might be 
needed for the PSA value to return to baseline. PSA ele-
vations can also occur as the result of urethral procedures 
with instrumentation, or following prostatic manipu-
lation, such as the DRE. Therefore, in a patient with an in-
creased PSA level and any recent history of either acute in-
fection, urinary retention, or urinary tract manipulation, 
prostate biopsy is not mandatory, and a period of time is 
required to obtain an accurate PSA level [19-21]. Accordin-
gly, urinary tract infection and urinary retention were ex-
clusion criteria in our study. 
The limits of our study are the relatively small number 
of patients and the retrospective design. To validate this 
cutoff value, a prospective study is needed to compare pa-
tients who underwent prostate biopsy with those who did 
not. 
CONCLUSIONS
Our results suggest the possibility for a biopsy-free diag-
nosis of prostate cancer, with the criterion of a PSA level 
＞100 ng/ml and evidence of advanced disease in imaging 
studies. We still recommend that any patient who is consid-
ered a candidate for surgery or radiation, despite a high 
PSA level, should undergo biopsy. Nevertheless, because 
prostate needle biopsy can be associated with several ad-
verse effects, if elderly patients with poor general medical 
condition present with an extremely elevated serum PSA 
level, a tissue diagnosis of prostate cancer may not be re-
quired for starting androgen deprivation therapy.
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